Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 23, 2026.

The Intriguing Role of Interleukin 13 in the Pathophysiology of Asthma

Giancarlo Marone, Francescopaolo Granata, Valentina Pucino and 5 more

Frontiers in Pharmacology · 2019 · Review · CC BY

doi:10.3389/fphar.2019.01387

Abstract

Approximately 5-10% of asthmatic patients worldwide suffer from severe asthma. Experimental and clinical studies have demonstrated that IL-13 is an important cytokine in chronic airways inflammation. IL-13 is involved in Th2 inflammation and has been identified as a possible therapeutic target in the treatment of asthma. Two different human monoclonal antibodies (mAbs) anti-IL-13 (tralokinumab and lebrikizumab) block binding and signaling of IL-13 to its receptors, IL-13Rα1 and IL-13Rα2. Several randomized, double-blind, placebo-controlled multicenter studies have evaluated the safety and efficacy of tralokinumab and lebrikizumab in the treatment of adult patients with severe asthma, but all have failed to meet their primary endpoints. No serious adverse events related to the treatment with these anti-IL-13 mAbs have been reported in these studies. These negative clinical results contrast with positive findings from blocking IL-13 signaling in experimental models of asthma, raising doubts about the transferrable value of some models. Interestingly, dupilumab, a mAb which blocks both IL-4 and IL-13 signaling reduces exacerbation rates and improves lung function in severe asthmatics. These results suggest that IL-4 and IL-13 share some, but not all functional activities in airway inflammation. Tralokinumab might show efficacy in a highly selected cohort of asthmatics characterized by overexpression of IL-13.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 23, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Bronchial asthma is a chronic inflammatory disorder of the airways characterized by reversible airflow obstruction, bronchial hyperreactivity (BHR), mucus overproduction, angiogenesis, and airway remodeling. Asthma is a common disorder resulting in substantial morbidity, healthcare expenditure, and death. Worldwide, up to 300 million people are affected by asthma, making it one of the most common chronic diseases (World Health Organization. Global surveillance, prevention, and control of chronic respiratory diseases. http://www.who.int/gard/publications/GARD/2007) and approximately 250,000 people die from asthma each year. In the majority of patients, asthma can be controlled by combinations of inhaled glucocorticoids (ICS), short- or long-acting ß2-adrenergic agonists (LABA), long-acting muscarinic antagonists, and leukotriene receptor antagonists, according to the Global Initiative for Asthma (GINA) guidelines (GINA http://www.ginasthma.org/pdf). However, in approximately 15% of patients, the disease is refractory to conventional treatments and results in hospital admissions due to severe exarcerbations.

As with many chronic inflammatory diseases, clinicians now realize that the traditional classification of asthma has been an oversimplification. Different asthma phenotypes, each with distinct pathophysiology, are now being defined as asthma endotypes. The heterogeneity of different forms of asthma reflects the involvement of different immune cell populations and inflammatory mediators. Asthma can be classified according to two major endotypes: “T2-high” asthma is characterized by increased levels of type 2 inflammation mainly mediated by mast cells, eosinophils, basophils, T-helper 2 cells, group 2 innate lymphoid cells (ILC2s), and immunoglobulin E (IgE)-producing B cells. Patients with T2-high asthma have eosinophilia and other signs of type 2 inflammation including high levels of IL-4 and IL-13. Increased blood and sputum levels of eosinophils, serum IgE, and the fraction of exhaled nitric oxide (FeNO) have been associated with the mechanisms of T2-high asthma. Another feature is the high expression of the prostaglandin D2 receptor chemoattractant receptor-homologous molecule (CRTH2) on Th2 lymphocytes. “T2-low” asthma is less well characterized and may include several different endotypes. It has been suggested that Th1 and Th17 pathways and neurogenic inflammation may be involved.

Levels of IgE, blood eosinophils and FeNO can be useful to guide the selection of monoclonal antibodies (mAbs) in the treatment of different forms of severe uncontrolled asthma. For example, several studies have demonstrated the safety and efficacy of mAbs blocking IL-5 (i.e., mepolizumab and reslizumab) for treatment of patients with severe eosinophilic asthma. Benralizumab, a mAb against IL-5Rα, expressed on the surface of human eosinophils, is particularly effective in patients with severe asthma with high blood eosinophils. Because IgE and the high affinity receptor for IgE (FcεRI) play a central role in atopic asthma, a mAb anti-IgE (omalizumab) is indicated for the treatment of patients (aged ≥ 12 years) with moderate-to-severe uncontrolled allergic asthma. Serum concentrations of IgE are used to guide this treatment.

IL-4 and IL-13 were among the first identified cytokines orchestrating Th2 inflammation. IL-4 and IL-13 are potent mediators of type 2 inflammation with both overlapping and distinct functions. Pascolizumab, a mAb selectively blocking IL-4, failed to produce positive effects. Two mAbs blocking IL-13 (i.e., anrukinzumab, lebrikizumab) have shown marginal effects in the treatment of asthmatic patients. Another mAb anti-IL-13 (i.e., tralokinumab, AstraZeneca) failed to reduce asthma exacerbation rate in severe uncontrolled asthmatics. Considering the individual relevance of IL-4 and IL-13 in the pathogenesis of asthma, these results are surprising and intriguing. A simplistic explanation is that individual blockade of IL-4 or IL-13 is insufficient to inhibit the complex orchestration of allergic inflammation and clinical consequences in severe asthma. This hypothesis is indirectly supported by the efficacy of dupilumab, which inhibits both IL-4 and IL-13 signaling mediated by IL-4Rα, in patients with severe uncontrolled asthma.

In this review we analyze the biological and immunological effects of IL-13 in the context of experimental models of asthma and in asthmatic patients. Despite promising findings in several experimental models of allergic inflammation, the results of multicenter studies evaluating the efficacy of anti-IL-13 mAbs in patients with asthma were surprisingly negative. Possible explanations of these discrepancies are discussed.

Biological and Immunological Effects of Interleukin 13

IL-13 is a pleiotropic cytokine originally cloned from activated human T-lymphocytes. The human IL13 gene is located on chromosome 5q31-33 in the cluster of genes encoding IL-4, IL-3, IL-5, IL-9, and granulocyte-macrophage colony-stimulating factor (GM-CSF). The gene encoding IL-13 is upstream of the IL4 gene, leading to the speculation that these genes arose as a duplication event during evolution. However, IL-13 has only 25% homology with IL-4 thus explaining why these cytokines share some, but not all functional properties. IL-13 can be produced by stimulated Th2 cells, B lymphocytes, CD8+ cells, type 2 ILCs, alveolar macrophages, human mast cells, and basophils.

Figure 1 schematically illustrates the complex receptor system which mediates the signaling of IL-4 and IL-13. The IL-4Rα subunit is a component of both the type I and type II receptors. Type I receptors are composed of the IL-4Rα subunit complexed with common γ chain (γc); this receptor binds to IL-4 and is expressed on cells of hematopoietic stem cell origin. The type II receptor complex consists of IL-4Rα partnering with IL-13Rα1 and is found on many non-hematopoietic cells, such as bronchial epithelial cells, smooth muscle cells, fibroblasts, and keratinocytes. IL-4 signals through both the type I and type II receptor complexes whereas IL-13 signals only through the type II complex, because IL-13 binds to IL-13Rα1, whereas IL-4 primarily binds to IL-4Rα. In addition, the two cytokines have different functions and signaling. IL-4Rα, γc, and IL-13Rα1 all contain proline rich regions that can bind the Janus kinases JAK1, JAK2, JAK3, and TYK2. In hematopoietic cells that express γc and the associated JAK3, IL-4 binding to type I receptor results in the activation of JAK1, JAK2, and JAK3. IL-4 and IL-13 binding to type II receptor activate JAK1, JAK2, and TYK2. Activation of JAKs results in phosphorylation of cytoplasmic tyrosines leading to the recruitment of STAT6 to the receptor, followed by its phosphorylation and activation. The activation of STAT6 is the primary signaling event in the response to IL-4 or IL-13. In certain experimental conditions STAT1 and STAT3 can also be activated by both IL-4 and IL-13. The cytoplasmic domain of human IL-13Rα1 contains two tyrosine residues, which might serve as docking sites for STAT3. Phosphorylated STAT6 and STAT3 monomers dimerize and then translocate to the nucleus, bind to specific DNA elements to regulate transcription.

LaPorte and collaborators have examined in detail the molecular and structural basis of the IL-4/IL-13 receptor system. They demonstrated that IL-4 first binds to IL-4Rα to form a binary complex which then binds to the γc to form the functional ternary complex (type I receptor). IL-4 and IL-13 can also bind with high affinity to IL-4Rα and IL-13Rα1, respectively (type II receptor). The authors also compared the kinetics and potency of IL-4 and IL-13 signaling. IL-4 induced tyrosine phosphorylation of STAT6 more rapidly and more potently than IL-13. The latter observation was supported by previous experiments on cultured airway smooth muscle cells. IL-4 is a central mediator for Th2 cell polarization, initiation of IgE synthesis, and recruitment of eosinophils. Although IL-13 has some redundancy in these effects, this cytokine has additional roles in mediating goblet cell hyperplasia, airway smooth muscle contractility, collagen deposition, and fibrosis.

There is a distinct IL-13Rα2 subunit, to which only IL-13 binds. Initially this receptor was considered a decoy receptor involved in removing IL-13 by internalization. Although the IL-13Rα2 lacks canonical JAK-STAT signaling activity, this hypothesis has come into question because several studies have shown that, under certain circumstances, IL-13Rα2 can mediate IL-13 signaling. In human airways, it was found that IL-13Rα2 is involved in IL-13 signaling through the transcription factor activator protein-1 (AP-1) to induce the activation of TGF-β. Recently, it has been demonstrated that IL-13 induced phosphorylation of ERK1/2 and the downstream activation of AP-1-related genes in human nasal epithelial cells. The authors proposed that engagement of IL-13Rα2 by IL-13 activates mitogen-activated protein ERK1/2 pathway and downstream AP-1-related gene C-JUN.

Figure 2 shows schematically that IL-13 is produced by several immune cells and has many diverse functions on a wide variety of cell types relevant to the pathogenesis of allergic disorders. IL-13 can be produced by activated ILC2, Th2 cells, mast cells, macrophages, basophils, eosinophils, and B cells. In human B cells IL-13 has similar effects as IL-4, including promoting B cell proliferation and inducing class switching to IgE and IgG4 in combination with CD40/CD40L and inducing expression of the low-affinity IgE receptor CD23. In macrophages IL-13 favors the M2 polarization. IL-13 promotes survival, activation, and recruitment of eosinophils. In addition, IL-13 stimulates eosinophil trafficking from the peripheral blood to the site of inflammation by inducing the production of IL-5 and eosinophil chemokines such as eotaxins IL-13 promotes FcεRI expression and proliferation of human mast.

IL-13 also has important effects on non-hematopoietic cells, including endothelial cells, smooth muscle cells, fibroblasts, epithelial cells, and sensory neurons. IL-13 is a potent inducer of vascular cell adhesion molecule-1 (VCAM-1) on endothelial cells, an important aspect in the recruitment of eosinophils. In addition, IL-13 increases the expression of ß1 integrin and VCAM-1 on human lung fibroblasts and increases muscular contraction in response to acetylcholine. Furthermore, IL-13 enhances proliferation and cholinergic-induced contraction of smooth muscle cells and induces collagen synthesis in human fibroblasts contributing to airways remodeling. In epithelial cells, IL-13 is a potent inducer of eotaxin. Moreover, IL-13 induces mucus overproduction and goblet cell metaplasia. IL-13 induces vascular endothelial growth factors (VEGFs) which are pro-angiogenic factors relevant in bronchial asthma. Recently, it has been demonstrated that IL-13 and IL-4 directly activate mouse and human sensory neurons which express IL-13Rα1 and IL-4Rα.

Interleukin 13 in Experimental Models of Asthma

Seminal studies in animal models of allergic asthma demonstrated that selective neutralization of IL-13 reduced airway hypersensitivity (AHR), bronchoalveolar lavage (BAL) eosinophils, and mucus overproduction. Furthermore, IL-13 delivery to the airways caused all of these effects. Overexpression of IL-13 in the lung of mice caused mucus hypersecretion, subepithelial fibrosis, eotaxin production, and eosinophilic infiltration. Interestingly, mice with targeted deletion of IL-13 failed to develop allergen-induced AHR, despite the presence of eosinophilic pulmonary infiltration. Mice lacking STAT6 were protected from pulmonary effects of IL-13. Importantly, reconstitution of STAT6 in epithelial cells only was sufficient for IL-13-induced AHR and mucus production in the absence of inflammation and fibrosis. Administration of anti-IL-13 in a mouse model of chronic asthma inhibited eosinophil recruitment in the airways, goblet cell hyperplasia, and subepithelial fibrosis, but only marginally inhibited AHR. In another study, blockade of IL-13 with sIL-13Rα2-human IgG fusion protein inhibited AHR associated with brief allergen exposure, but did not modify AHR associated with chronic airway remodeling.

An IL-13 vaccine prepared by inserting a murine IL-13 peptide into a viral carrier protein, induced sustained and intense anti-IL-13 IgG antibodies, associated with inhibition of ovalbumin (OVA)-induced acute airway allergic responses. In a more recent study, the same experimental approach suppressed BAL IL-13 concentration and eosinophils, subepithelial collagen deposition, and mucus hyperproduction. Interestingly, while IL-13 vaccine inhibited AHR development, it did not revert AHR. The latter findings suggest that IL-13 may be crucial in the development, but not in the maintenance of airway hyperesponsiveness.

Il13ra2 gene silencing or blockade of IL-13Rα2 signaling led to marked downregulation of TGF-β1 production and collagen deposition in a model of lung fibrosis. In IL-13Rα2-deficient mice, AHR and airway inflammation (i.e., mucus production and BAL eosinophils) were attenuated compared to wild type mice following house dust challenge. More recently, it was reported that, in IL-4Rα-deficient mice, IL-13, but not IL-4, was required for development of OVA-mediated AHR and goblet cell hyperplasia. Munitz and collaborators studying Il13ra1 -/- mice found that IL-13Rα1 is critical for baseline IgE production, AHR, mucus production, and eotaxin production. By contrast, Th2 and IgE responses to antigen were IL-13Rα1-independent.

In a novel mouse model of non-allergic asthma overexpression of the activator protein-1 (AP-1) subunit Fra2, caused airway inflammation with IL-13 overexpression, BAL eosinophilia, mucus hyperproduction, AHR, and peribronchial collagen deposition. Administration of anti-IL-13 antibody markedly decreased STAT6 phosphorylation in the lung, BAL eosinophilia, and goblet cell hyperplasia. However, peribronchial collagen deposition and bronchial smooth muscle width were not affected by anti-IL-13 administration. The interesting results obtained in this experimental model may be more reflective of severe asthma which exhibit poor response to mAb anti-IL-13.

Genetic deletion of the IL-33 receptor in a mouse model of experimental asthma increased TSLP production, which stimulated the emergence of IL-13+ ILC2s and lung mast cells leading to airway hyperresponsiveness.

Collectively, the results derived from different experimental models indicate that IL-13 plays an important role in the development of several aspects of asthma. However, it is becoming evident that IL-13 neutralization is not sufficient to reverse certain aspects of airway inflammation once they are established.

Interleukin 13 Expression in Asthmatic Patients

Increased concentration of IL-13 have been found in the blood, sputum, bronchial mucosa, and BAL fluid of asthmatic patients compared to healthy individuals. Increased IL-13 expression in asthma was confirmed by IL-13 mRNA overexpression and by ex vivo stimulation of sputum T cells. Following allergen challenge, IL-13 is increased in BAL. Ex vivo BAL T cells express IL-13 mRNA; expression is inversely related to forced expiratory volume in 1 s (FEV1). Several studies have shown that IL-13 is expressed in bronchial biopsies in patients with asthma. IL-13+ ILC2 were increased in the circulation of asthmatic patients with levels correlating with asthma severity. High production of IL-13 by cord blood CD4+ T cells is a predictor of development of atopic disorders.

Polymorphisms in the Interleukin 13/Interleukin 4 Receptor Complex Associated With Asthma

Polymorphisms have been identified both in the IL-13 promoter (IL-13-1112 T) and the coding region (IL-13+Arg 130Gen, IL-13+2044G > A) in asthmatic patients. One of the polymorphisms (Arg 130 Gln) (A/G) identified occur in the region critical for receptor-ligand interactions. Multiple polymorphism in IL-4R gene have also been identified and associated with asthma. Recently, three meta-analyses of IL-13 polymorphisms in adults and children suggested that the IL-13+1923 C/T polymorphism is associated with increased risk of asthma.

Tralokinumab and Lebrikizumab for the Treatment of Severe Uncontrolled Asthma

Several anti-IL-13 mAbs (anrukinzumab, lebrikizumab, tralokinumab) have provided an opportunity to investigate the role of this cytokine in the pathophysiology of severe asthma, as well as assessing treatment response. A phase 1 study evaluated the pharmacokinetics, safety, and tolerability of tralokinumab in asthmatic patients receiving three different i.v. doses: 1 mg/kg, 5 mg/kg, or 10 mg/kg. Despite the small sample size, pharmacokinetics were linear over the dose range studied. The half-life was found to be 2–3 weeks and tralokinumab exhibited an acceptable safety profile.

A phase 2a, randomized, double-blind, placebo-controlled, parallel-group, multicenter study investigated the effects of different dose regimens of tralokinumab in 194 adults with moderate-to-severe asthma inadequately controlled with standard therapy. Three dose regimens were evaluated: 47 patients received s.c. tralokinumab 150 mg, 51 patients received tralokinumab 300 mg, 48 subjects received tralokinumab 600 mg, and 48 patients received placebo. The primary endpoint was the change from baseline in mean Asthma Control Questionnaire score (ACQ-6) at week 13. Secondary endpoints were change in FEV1, pre-bronchodilator lung function, patient-reported outcomes (PROs), rescue β2-agonist use, and safety outcomes. Mean ACQ-6 score improved in all treatment groups, from baseline to week 13. These changes in ACQ-6 persisted through week 24 and were greater in active patients with higher IL-13 sputum concentrations compared with subjects with lower IL-13 sputum concentrations or subjects receiving placebo. Improvement in FEV1 were higher in patients with peripheral eosinophil counts ≥ 300 cells/ml. Pulmonary function improvements were higher in tralokinumab patients with higher sputum IL-13 (≥ 10 pg/ml-1) compared to tralokinumab patients with lower sputum IL-13 (≤10 pg/ml-1) and patients receiving placebo. However, there was no significant difference in asthma exacerbation rate. The authors defined asthma exacerbations as either a progressive increase of asthma symptoms (cough, wheeze, chest tightness, and/or shortness of breath) or a reduction of >20% in peak expiratory flow or FEV1 from baseline that did not resolve after the initiation of rescue medications and resulted in an administration of systemic glucocorticoids.

The phase 2b clinical trial run by Brightling and colleagues evaluated safety and tolerability profile and the reduction in exacerbation rate and FEV1 improvement. The authors randomized 452 severe asthmatic patients, all with two-to-six asthma exacerbations in the previous year, to receive tralokinumab (300 mg s.c. either every 2 weeks or every 2 weeks for 3 months and then every 4 weeks) or placebo as add-on therapy for 1 year. At the end of the study, they reported no changes in the annual exacerbation rate at week 52 (primary endpoint) in patients treated with tralokinumab, either every 2 or 4 weeks, versus placebo or in time to first exacerbation. The authors defined asthma exacerbation as an increase in asthma symptoms resulting in use or increase in dose of systemic glucocorticoids for three or more consecutive days. Similarly, secondary endpoints such as improvements in prebronchodilator FEV1, ACQ-6, and AQLQ(S) were not significant in patients treated with tralokinumab compared with placebo. They found a significant improvement in FEV1 in patients treated with tralokinumab every 2 weeks. In this study measurement of serum dipeptidyl peptidase-4 (DPP-4) and periostin concentrations were included as a predictive candidate biomarkers before the study was unmasked. Subgroup analyses of patients receiving tralokinumab every 2 weeks with airway reversibility at baseline, but not receiving oral glucocorticoids, showed some clinical improvements in the subgroup who had raised serum DPP-4 and periostin. These preliminary results suggested that certain subpopulations of patients with severe asthma might respond to tralokinumab treatment.

A phase 2 multicenter, double-blind, randomized, placebo-controlled trial evaluated the effects of tralokinumab on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS). In this study, participants aged 18–75 years were randomly assigned to receive tralokinumab (300 mg s.c. every 2 weeks) or placebo. The primary outcome measure was change from baseline to week 12 in bronchial biopsy eosinophil count. Secondary outcome measures included change in blood and sputum eosinophil counts. Exploratory outcomes included FeNO and blood IgE concentrations. Tralokinumab did not affect bronchial, peripheral blood, or eosinophil counts compared to placebo at week 12. FeNO concentrations and total blood IgE were significantly reduced. The authors concluded that IL-13 is not crucial for eosinophilic airway inflammation control in patients with moderate-to-severe asthma.

Two large phase 3 clinical trials, STRATOS 1 and STRATOS 2, explored the use of periostin and DPP-4 as biomarkers of IL-13-driven inflammatory patterns in patients aged 12–75 years with severe uncontrolled asthma treated with tralokinumab (300 mg s.c. every 2 weeks for 52 weeks) or placebo. The primary endpoint was the annualized asthma exacerbation rate reduction at week 52 in the all-comers population for STRATOS 1 and in the biomarker-positive population for STRATOS 2. The results of both trials confirmed that tralokinumab did not improve the annual asthma exacerbation rate in the all-comers population with severe asthma. In contrast to the preliminary results of the phase 2 trial, periostin and DPP-4 were not shown to predict response to tralokinumab. In both trials, tralokinumab-treated participants had a small increase in blood eosinophil counts from baseline, whereas placebo-treated participants did not. A recent meta-analysis of six randomized clinical trials suggested that tralokinumab was well tolerated and modestly improved FEV1 but did not reduce asthma exacerbations in severe uncontrolled asthma.

Given the need to reduce oral glucocorticoid administration in patients with severe asthma, treatments that may allow tapering of glucocorticoids without loss of disease control are needed. A 40-week, randomized, double-blind trial (TROPOS) evaluated the oral glucocorticoid-sparing potential of tralokinumab in patients with severe, uncontrolled asthma requiring maintenance glucocorticoid treatment plus ICS/LABA. One hundred forty patients were randomized to tralokinumab (300 mg s.c. every 2 weeks) or placebo. The primary endpoint was percentage change from baseline in average glucocorticoid dose at week 40, while maintaining asthma control. Secondary endpoints included patients with a prescribed maintenance glucocorticoid dose of ≤ 5 mg, those with greater than 50% reduction in prescribed maintenance glucocorticoids dose and annual asthma exacerbation rate. An asthma exacerbation was defined as worsening of asthma that required a temporary increase in systemic glucocorticoids for ⩾3 days or that resulted in an emergency-room or urgent-care visit that led to a temporary increase in systemic glucocorticoids for ⩾3 days to treat symptoms or an inpatient hospitalization due to asthma. There were no significant between-group differences for primary and secondary endpoints. Reporting of adverse events and serious adverse events were similar for the tralokinumab and placebo groups.

A randomized, double-blind, placebo controlled study examined the effects of another anti-IL-13 mAb, lebrikizumab (250 mg s.c. once monthly for 6 months), on change in prebronchodilator FEV1 from baseline to week 12 in 219 adults with uncontrolled asthma. Lebrikizumab treatment was associated with greater improvement in percent change in FEV1 in patients with high pretreatment levels of serum periostin compared to patients with low periostin levels. In two replicate studies (LUTE and VERSE) in patients with moderate-to-severe uncontrolled asthma, lebrikizumab (37.5, 125 or 250 mg s.c. every 4 weeks) reduced asthma exacerbation rate by 60% compared to placebo in periostin-high patients and by 5% in periostin-low patients. In these studies the authors defined asthma exacerbation as new or increased asthma symptoms that led to treatment with systemic glucocorticoids or to hospitalization. Two replicate, phase 3 trials (LAVOLTA1 and LAVOLTA2) explored the use of periostin and eosinophilia (≥ 300 cells/µl) as biomarkers of IL-13-driven inflammatory patterns in patients with severe uncontrolled asthma treated with lebrikizumab (37.5 mg or 125 mg s.c. once every 4 weeks for 52 weeks or placebo). The primary endpoint was the reduction in the rate of asthma exacerbations over 52 weeks in biomarker-high patients (periostin ≥ 50 ng/ml or blood eosinophils ≥ 300 cells/µl. In contrast to the preliminary results of phase 2 trials, lebrikizumab did not consistently show significant reduction in asthma exacerbations in biomarker-high patients.

Anti-Interleukin 13 in Nasal Polyposis

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a common and relevant comorbidity for severe asthma. The prevalence of CRSwNP is greater in asthmatics compared to the general population and it increases with the severity of asthma, with the highest prevalence rates in non-atopic, late-onset, severe asthmatics. More than 60% of patients with CRSwNP have asthma. Moreover, CRWwNP is one of the significant determinants of poor asthma control and a hallmark of refractory eosinophilic asthma. The clinical evidence of a strong relationship between CRSwNP and severe asthma raises the possibility of a shared pathogenesis. In particular both diseases seem to be dependent on eosinophilic inflammation mediated by epithelial cytokines such as thymic stromal lymphopoietin (TSLP), IL-25, and IL-33 secreted as a consequence of epithelial damage. The latter activation is mediated by ILC2 which produce several type 2 cytokines such as IL-13 and IL-5. Recently, it has been reported that there were significant increases in IL-13, IL-13Rα1, and IL-13Rα2 mRNA and protein concentrations in nasal polyp epithelium. Moreover, IL-13 treatment resulted in mucus overproduction and impairment of ciliary function of human nasal epithelial cells. Therefore, an anti-IL-13 strategy, such as tralokinumab, may be helpful in the management of patients with nasal polyps. Unfortunately, there are no clinical trials of treatment of CRSwNP with anti-IL13 mAbs. Interestingly, patients treated with dupilumab, a mAb against IL-4Rα, the common receptor for both IL-4 and IL-13 had a significant reduction in polyp size and improvement in symptoms and nasal and olfactory function.

Concluding Remarks and Perspectives

Three phase 2 clinical trials and three phase 3 clinical trials have shown that tralokinumab did not lower the annual exacerbation rate and did not improve ACQ-6 scores compared to placebo in severe uncontrolled asthmatic patients. These negative findings parallel the results of two replicate, phase 3 trials with lebrikizumab. These negative results are surprising given the wide spectrum of pro-inflammatory and pro-fibrogenic activities of IL-13 in experimental models of asthma and in asthmatic patients.

There are several possible explanations of these negative findings. First, it is likely that IL-13 is not the main cytokine involved in the complex network of severe asthma pathogenesis, meaning blocking it alone is ineffective. Second, as shown in several trials, the biomarkers (e.g., periostin, DPP-4, peripheral eosinophil count) used to identify responders to anti-IL-13 therapy are not optimal. Third, in both experimental models and clinical studies blocking IL-13 appears to have no effect on reducing tissue or blood eosinophilia, the pathophysiological feature most closely linked to asthma exacerbations. Fourth, perhaps the route of administration (i.e., s.c.) and the size of the anti-IL-13 mAb particles are not ideal. For instance, it has been reported the preliminary efficacy of a nebulized inhaled anti-IL-13 mAb antigen-binding fragment in macaque model of asthma. Finally, we cannot exclude the possibility that some of these negative findings could be due to the inclusion in clinical trials of patients with Th2-low asthma.

Interestingly, the initial attempts to develop cytokine therapies for asthma focusing on antagonizing IL-4 were also unsuccessful, as was an attempt to block the combined receptor. By contrast, dupilumab, which binds to IL-4Rα and consequently blocks both IL-4 and IL-13 signaling, decreases asthma exacerbations and improves respiratory symptoms in patients with persistent asthma. These observations suggest that only the effective simultaneous blockade of signaling from two main cytokines (i.e., IL-4 and IL-13) is effective in the treatment of severe asthma. Using allergic preclinical models, it has been demonstrated that the combined blockade of the IL-13 and IL-33 pathways leads to a greater inhibition of type 2 inflammation over inhibition of either pathway alone. Similarly, co-blockade of IL-13 and IL-25 attenuated AHR, eosinophil infiltration in the lung, and mucus hyperproduction in a mouse model of OVA-induced asthma. Recently, a novel dual antagonist anti-TSLP/IL-13 bispecific antibody has been described. It will be interesting to see whether combinatorial blockade of multiple cytokines, including IL-13, may yield additional efficacy over single-axis therapies alone.

It is intriguing that IL-13 blockade modulates several aspects of different experimental models of allergic asthma. Moreover, recent results demonstrate that anti-IL-13 antibody improves bronchial hyperresponsiveness and mucus production in a mouse model of non-allergic asthma. These positive experimental results contrast with negative results in the treatment of asthmatic patients with different anti-IL-13 mAbs (tralokinumab and lebrikizumab). These findings highlight that the results from murine studies do not always predict clinical effectiveness.

In conclusion, despite several efforts, attempts to demonstrate a benefit of anti-IL-13 in patients with severe asthma remain unproven. While this may be because the right predictive biomarkers or patient phenotypes have not yet been identified, it is perhaps more likely that there is enough redundancy in the pathophysiology of severe asthma to persist without IL-13. This is not to say, at this stage, that another clinical indication might not be found for IL-13-blocking drugs in future.

Author Contributions

All authors contributed to reviewing the current literature and writing of the manuscript and approved the final version of the paper. Conceptualization: GM, GS, GV. Original draft preparation: GM, GS, GV. Final editing: GM, FG, VP, AP, EH, SL, GS, GV.

Funding

This work was supported in part by grants from CISI-Lab Project (University of Naples Federico II) and TIMING Project (Regione Campania).

Conflict of Interest

EH is advisory board member for AstraZeneca, Sanofi- Genzyme, Novartis, GSK, Circassia, Nestlè, and Purina.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 174

  1. 1.

    Akaiwa M. Yu B. Umeshita-Suyama R. Terada N. Suto H. Koga T. (2001 ). Localization of human interleukin 13 receptor in non-haematopoietic cells. Cytokine 13, 75–84.

    Not in our library10.1006/cyto.2000.0814

  2. 2.

    Alasandagutti M. L. Ansari M. S. Sagurthi S. R. Valluri V. Gaddam S. (2017 ). Role of IL-13 genetic variants in signalling of asthma. Inflammation 40, 566–577.

    Not in our library10.1007/s10753-016-0503-3

  3. 3.

    Amelink M. de Groot J. C. de Nijs S. B. Lutter R. Zwinderman A. H. Sterk P. J. (2013 ). Severe adult-onset asthma: a distinct phenotype. J. Allergy Clin. Immunol. 132, 336–341.

    Not in our library10.1016/j.jaci.2013.04.052

  4. 4.

    Arima K. Umeshita-Suyama R. Sakata Y. Akaiwa M. Mao X. Q. Enomoto T. (2002 ). Upregulation of IL-13 concentration in vivo by the IL13 variant associated with bronchial asthma. J. Allergy Clin. Immunol. 109, 980–987.

    Not in our library10.1067/mai.2002.124656

  5. 5.

    Aron J. L. Akbari O. (2017 ). Regulatory T cells and type 2 innate lymphoid cell-dependent asthma. Allergy 72, 1148–1155.

    Not in our library10.1111/all.13139

  6. 6.

    Bachert C. Mannent L. Naclerio R. M. Mullol J. Ferguson B. J. Gevaert P. (2016 ). Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA 315, 469–479.

    Not in our library10.1001/jama.2015.19330

  7. 7.

    Bagnasco D. Ferrando M. Varricchi G. Passalacqua G. Canonica G. W. (2016 ). A Critical Evaluation of Anti-IL-13 and Anti-IL-4 Strategies in Severe Asthma. Int. Arch. Allergy Immunol. 170, 122–131.

    Not in our library10.1159/000447692

  8. 8.

    Bagnasco D. Ferrando M. Varricchi G. Puggioni F. Passalacqua G. Canonica G. W. (2017 ). Anti-Interleukin 5 (IL-5) and IL-5Ra biological drugs: efficacy, safety, and future perspectives in severe eosinophilic asthma. Front. Med. (Lausanne) 4, 135.

    Not in our library10.3389/fmed.2017.00135

  9. 9.

    Barcelo B. Pons J. Fuster A. Sauleda J. Noguera A. Ferrer J. M. (2006 ). Intracellular cytokine profile of T lymphocytes in patients with chronic obstructive pulmonary disease. Clin. Exp. Immunol. 145, 474–479.

    Not in our library10.1111/j.1365-2249.2006.03167.x

  10. 10.

    Bel E. H. Wenzel S. E. Thompson P. J. Prazma C. M. Keene O. N. Yancey S. W. (2014 ). Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N. Engl. J. Med. 371, 1189–1197.

    Not in our library10.1056/nejmoa1403291

  11. 11.

    Berry M. A. Parker D. Neale N. Woodman L. Morgan A. Monk P. (2004 ). Sputum and bronchial submucosal IL-13 expression in asthma and eosinophilic bronchitis. J. Allergy Clin. Immunol. 114, 1106–1109.

    Not in our library10.1016/j.jaci.2004.08.032

  12. 12.

    Bhattacharjee A. Shukla M. Yakubenko V. P. Mulya A. Kundu S. Cathcart M. K. (2013 ). IL-4 and IL-13 employ discrete signaling pathways for target gene expression in alternatively activated monocytes/macrophages. Free Radic. Biol. Med. 54, 1–16.

    Not in our library10.1016/j.freeradbiomed.2012.10.553

  13. 13.

    Bjermer L. Lemiere C. Maspero J. Weiss S. Zangrilli J. Germinaro M. (2016 ). Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest 150, 789–798.

    Not in our library10.1016/j.chest.2016.03.032

  14. 14.

    Bochner B. S. Klunk D. A. Sterbinsky S. A. Coffman R. L. Schleimer R. P. (1995 ). IL-13 selectively induces vascular cell adhesion molecule-1 expression in human endothelial cells. J. Immunol. 154, 799–803.

    Not in our library

  15. 15.

    Bodey K. J. Semper A. E. Redington A. E. Madden J. Teran L. M. Holgate S. T. (1999 ). Cytokine profiles of BAL T cells and T-cell clones obtained from human asthmatic airways after local allergen challenge. Allergy 54, 1083–1093.

    Not in our library10.1034/j.1398-9995.1999.00889.x

  16. 16.

    Boita M. Bucca C. Riva G. Heffler E. Rolla G. (2016 ). Release of Type 2 Cytokines by Epithelial Cells of Nasal Polyps. J. Immunol. Res. 2016, 2643297.

    Not in our library10.1155/2016/2643297

  17. 17.

    Boniface S. Koscher V. Mamessier E. El Biaze M. Dupuy P. Lorec A. M. (2003 ). Assessment of T lymphocyte cytokine production in induced sputum from asthmatics: a flow cytometry study. Clin. Exp. Allergy 33, 1238–1243.

    Not in our library10.1046/j.1365-2222.2003.01762.x

  18. 18.

    Borriello F. Longo M. Spinelli R. Pecoraro A. Granata F. Staiano R. I. (2015 ). IL-3 synergises with basophil-derived IL-4 and IL-13 to promote the alternative activation of human monocytes. Eur. J. Immunol. 45, 2042–2051.

    Not in our library10.1002/eji.201445303

  19. 19.

    Borriello F. Galdiero M. R. Varricchi G. Loffredo S. Spadaro G. Marone G. (2019 ). Innate Immune Modulation by GM-CSF and IL-3 in Health and Disease. Int. J. Mol. Sci. 20, E834.

    Not in our library10.3390/ijms20040834

  20. 20.

    Brightling C. E. Chanez P. Leigh R. O'Byrne P. M. Korn S. She D. (2015 ). Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir. Med. 3, 692–701.

    Not in our library10.1016/s2213-2600(15)00197-6

  21. 21.

    Burd P. R. Thompson W. C. Max E. E. Mills F. C. (1995 ). Activated mast cells produce interleukin 13. J. Exp. Med. 181, 1373–1380.

    Not in our library10.1084/jem.181.4.1373

  22. 22.

    Burmeister Getz E. Fisher D. M. Fuller R. (2009 ). Human pharmacokinetics/pharmacodynamics of an interleukin-4 and interleukin-13 dual antagonist in asthma. J. Clin. Pharmacol. 49, 1025–1036.

    Not in our library10.1177/0091270009341183

  23. 23.

    Busse W. W. Brusselle G. G. Korn S. Kuna P. Magnan A. Cohen D. (2019 ). Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma. Eur. Respir. J. 53, 1800948.

    Not in our library10.1183/13993003.00948-2018

  24. 24.

    Cameron L. Webster R. B. Strempel J. M. Kiesler P. Kabesch M. Ramachandran H. (2006 ). Th2 cell-selective enhancement of human IL13 transcription by IL13-1112C>T, a polymorphism associated with allergic inflammation. J. Immunol. 177, 8633–8642.

    Not in our library10.4049/jimmunol.177.12.8633

  25. 25.

    Cao H. Zhang J. Liu H. Wan L. Zhang H. Huang Q. (2016 ). IL-13/STAT6 signaling plays a critical role in the epithelial-mesenchymal transition of colorectal cancer cells. Oncotarget 7, 61183–61198.

    Not in our library10.18632/oncotarget.11282

  26. 26.

    Castro M. Corren J. Pavord I. D. Maspero J. Wenzel S. Rabe K. F. (2018 ). Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N. Engl. J. Med. 378, 2486–2496.

    Not in our library10.1056/nejmoa1804092

  27. 27.

    Chachi L. Shikotra A. Duffy S. M. Tliba O. Brightling C. Bradding P. (2013 ). Functional KCa3.1 channels regulate steroid insensitivity in bronchial smooth muscle cells. J. Immunol. 191, 2624–2636.

    Not in our library10.4049/jimmunol.1300104

  28. 28.

    Chachi L. Abbasian M. Gavrila A. Alzahrani A. Tliba O. Bradding P. (2017 ). Protein phosphatase 5 mediates corticosteroid insensitivity in airway smooth muscle in patients with severe asthma. Allergy 72, 126–136.

    Not in our library10.1111/all.13003

  29. 29.

    Chatila T. A. (2004 ). Interleukin-4 receptor signaling pathways in asthma pathogenesis. Trends Mol. Med. 10, 493–499.

    Not in our library10.1016/j.molmed.2004.08.004

  30. 30.

    Chen W. Sivaprasad U. Tabata Y. Gibson A. M. Stier M. T. Finkelman F. D. (2009 ). IL-13R alpha 2 membrane and soluble isoforms differ in humans and mice. J. Immunol. 183, 7870–7876.

    Not in our library10.4049/jimmunol.0901028

  31. 31.

    Chen W. Sivaprasad U. Gibson A. M. Ericksen M. B. Cunningham C. M. Bass S. A. (2013 ). IL-13 receptor alpha2 contributes to development of experimental allergic asthma. J. Allergy Clin. Immunol. 132, 951–958 e951-956.

    Not in our library10.1016/j.jaci.2013.04.016

  32. 32.

    Choy D. F. Hart K. M. Borthwick L. A. Shikotra A. Nagarkar D. R. Siddiqui S. (2015 ). TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma. Sci. Transl. Med. 7, 301ra129.

    Not in our library10.1126/scitranslmed.aab3142

  33. 33.

    Chu H. W. Halliday J. L. Martin R. J. Leung D. Y. Szefler S. J. Wenzel S. E. (1998 ). Collagen deposition in large airways may not differentiate severe asthma from milder forms of the disease. Am. J. Respir. Crit. Care Med. 158, 1936–1944.

    Not in our library10.1164/ajrccm.158.6.9712073

  34. 34.

    Corne J. Chupp G. Lee C. G. Homer R. J. Zhu Z. Chen Q. (2000 ). IL-13 stimulates vascular endothelial cell growth factor and protects against hyperoxic acute lung injury. J. Clin. Invest. 106, 783–791.

    Not in our library10.1172/jci9674

  35. 35.

    Corren J. Lemanske R. F. Hanania N. A. Korenblat P. E. Parsey M. V. Arron J. R. (2011 ). Lebrikizumab treatment in adults with asthma. N. Engl. J. Med. 365, 1088–1098.

    Not in our library10.1056/nejmoa1106469

  36. 36.

    Cosmi L. Annunziato F. Galli M. I. G. Maggi R. M. E. Nagata K. Romagnani S. (2000 ). CRTH2 is the most reliable marker for the detection of circulating human type 2 Th and type 2 T cytotoxic cells in health and disease. Eur. J. Immunol. 30, 2972–2979.

    Not in our library10.1002/1521-4141(200010)30:10<2972::aid-immu2972>3.0.co;2-

  37. 37.

    Dakhama A. Collins M. L. Ohnishi H. Goleva E. Leung D. Y. Alam R. (2013 ). IL-13-producing BLT1-positive CD8 cells are increased in asthma and are associated with airway obstruction. Allergy 68, 666–673.

    Not in our library10.1111/all.12135

  38. 38.

    de Vries J. E. (1998 ). The role of IL-13 and its receptor in allergy and inflammatory responses. J. Allergy Clin. Immunol. 102, 165–169.

    Not in our library10.1016/s0091-6749(98)70080-6

  39. 39.

    Detoraki A. Staiano R. I. Granata F. Giannattasio G. Prevete N. de Paulis A. (2009 ). Vascular endothelial growth factors synthesized by human lung mast cells exert angiogenic effects. J. Allergy Clin. Immunol. 123, 1142–1149, 1149 e1141-1145.

    Not in our library10.1016/j.jaci.2009.01.044

  40. 40.

    Detoraki A. Granata F. Staibano S. Rossi F. W. Marone G. Genovese A. (2010 ). Angiogenesis and lymphangiogenesis in bronchial asthma. Allergy 65, 946–958.

    Not in our library10.1111/j.1398-9995.2010.02372.x

  41. 41.

    Doucet C. Brouty-Boye D. Pottin-Clemenceau C. Canonica G. W. Jasmin C. Azzarone B. (1998 ). Interleukin (IL) 4 and IL-13 act on human lung fibroblasts. Implication in asthma. J. Clin. Invest. 101, 2129–2139.

    Not in our library10.1172/jci741

  42. 42.

    Fahy J. V. (2015 ). Type 2 inflammation in asthma–present in most, absent in many. Nat. Rev. Immunol. 15, 57–65.

    Not in our library10.1038/nri3786

  43. 43.

    Fichtner-Feigl S. Strober W. Kawakami K. Puri R. K. Kitani A. (2006 ). IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat. Med. 12, 99–106.

    Not in our library10.1038/nm1332

  44. 44.

    Finkelman F. D. Shea-Donohue T. Morris S. C. Gildea L. Strait R. Madden K. B. (2004 ). Interleukin-4- and interleukin-13-mediated host protection against intestinal nematode parasites. Immunol. Rev. 201, 139–155.

    Not in our library10.1111/j.0105-2896.2004.00192.x

  45. 45.

    FitzGerald J. M. Bleecker E. R. Nair P. Korn S. Ohta K. Lommatzsch M. (2016 ). Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 388, 2128–2141.

    Not in our library10.1016/s0140-6736(16)31322-8

  46. 46.

    FitzGerald J. M. Bleecker E. R. Menzies-Gow A. Zangrilli J. G. Hirsch I. Metcalfe P. (2018 ). Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. Lancet Respir. Med. 6, 51–64.

    Not in our library10.1016/s2213-2600(17)30344-2

  47. 47.

    Fujisawa T. Joshi B. Nakajima A. Puri R. K. (2009 ). A novel role of interleukin-13 receptor alpha2 in pancreatic cancer invasion and metastasis. Cancer Res. 69, 8678–8685.

    Not in our library10.1158/0008-5472.can-09-2100

  48. 48.

    Fushimi T. Okayama H. Shimura S. Saitoh H. Shirato K. (1998 ). Dexamethasone suppresses gene expression and production of IL-13 by human mast cell line and lung mast cells. J. Allergy Clin. Immunol. 102, 134–142.

    Not in our library10.1016/s0091-6749(98)70064-8

  49. 49.

    Gandhi N. A. Pirozzi G. Graham N. M. H. (2017 ). Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev. Clin. Immunol. 13, 425–437.

    Not in our library10.1080/1744666x.2017.1298443

  50. 50.

    Gauvreau G. M. Boulet L. P. Cockcroft D. W. Fitzgerald J. M. Carlsten C. Davis B. E. (2011 ). Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. Am. J. Respir. Crit. Care Med. 183, 1007–1014.

    Not in our library10.1164/rccm.201008-1210oc

  51. 51.

    Genovese A. Borgia G. Bjorck L. Petraroli A. de Paulis A. Piazza M. (2003 ). Immunoglobulin superantigen protein L induces IL-4 and IL-13 secretion from human Fc epsilon RI+ cells through interaction with the kappa light chains of IgE. J. Immunol. 170, 1854–1861.

    Not in our library10.4049/jimmunol.170.4.1854

  52. 52.

    Gibbs B. F. Haas H. Falcone F. H. Albrecht C. Vollrath I. B. Noll T. (1996 ). Purified human peripheral blood basophils release interleukin-13 and preformed interleukin-4 following immunological activation. Eur. J. Immunol. 26, 2493–2498.

    Not in our library10.1002/eji.1830261033

  53. 53.

    Gould H. J. Sutton B. J. (2008 ). IgE in allergy and asthma today. Nat. Rev. Immunol. 8, 205–217.

    Not in our library10.1038/nri2273

  54. 54.

    Gour N. Wills-Karp M. (2015 ). IL-4 and IL-13 signaling in allergic airway disease. Cytokine 75, 68–78.

    Not in our library10.1016/j.cyto.2015.05.014

  55. 55.

    Graves P. E. Kabesch M. Halonen M. Holberg C. J. Baldini M. Fritzsch C. (2000 ). A cluster of seven tightly linked polymorphisms in the IL-13 gene is associated with total serum IgE levels in three populations of white children. J. Allergy Clin. Immunol. 105, 506–513.

    Not in our library10.1067/mai.2000.104940

  56. 56.

    Grunig G. Warnock M. Wakil A. E. Venkayya R. Brombacher F. Rennick D. M. (1998 ). Requirement for IL-13 independently of IL-4 in experimental asthma. Science 282, 2261–2263.

    Not in our library10.1126/science.282.5397.2261

  57. 57.

    Grunstein M. M. Hakonarson H. Leiter J. Chen M. Whelan R. Grunstein J. S. (2002 ). IL-13-dependent autocrine signaling mediates altered responsiveness of IgE-sensitized airway smooth muscle. Am. J. Physiol. Lung Cell Mol. Physiol. 282, L520–L528.

    Not in our library10.1152/ajplung.00343.2001

  58. 58.

    Guida G. Rolla G. Badiu I. Marsico P. Pizzimenti S. Bommarito L. (2010 ). Determinants of exhaled nitric oxide in chronic rhinosinusitis. Chest 137, 658–664.

    Not in our library10.1378/chest.09-0667

  59. 59.

    Gungl A. Biasin V. Wilhelm J. Olschewski A. Kwapiszewska G. Marsh L. M. (2018 ). Fra2 Overexpression in Mice Leads to Non-allergic Asthma Development in an IL-13 Dependent Manner. Front. Immunol. 9, 2018.

    Not in our library10.3389/fimmu.2018.02018

  60. 60.

    Hajoui O. Janani R. Tulic M. Joubert P. Ronis T. Hamid Q. (2004 ). Synthesis of IL-13 by human B lymphocytes: regulation and role in IgE production. J. Allergy Clin. Immunol. 114, 657–663.

    Not in our library10.1016/j.jaci.2004.05.034

  61. 61.

    Hanania N. A. Noonan M. Corren J. Korenblat P. Zheng Y. Fischer S. K. (2015 ). Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax 70, 748–756.

    Not in our library10.1136/thoraxjnl-2014-206719

  62. 62.

    Hanania N. A. Korenblat P. Chapman K. R. Bateman E. D. Kopecky P. Paggiaro P. (2016 ). Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir. Med. 4, 781–796.

    Not in our library10.1016/s2213-2600(16)30265-x

  63. 63.

    Hancock A. Armstrong L. Gama R. Millar A. (1998 ). Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung. Am. J. Respir. Cell Mol. Biol. 18, 60–65.

    Not in our library10.1165/ajrcmb.18.1.2627

  64. 64.

    Hart T. K. Blackburn M. N. Brigham-Burke M. Dede K. Al-Mahdi N. Zia-Amirhosseini P. (2002 ). Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma. Clin. Exp. Immunol. 130, 93–100.

    Not in our library10.1046/j.1365-2249.2002.01973.x

  65. 65.
    Chitinase 3-like 1 Regulates Cellular and Tissue Responses via IL-13 Receptor α2 · 2013
    Corrected
  66. 66.

    Heffler E. Pizzimenti S. Badiu I. Guida G. Ricciardolo F. L. Bucca C. (2013 ). Nasal nitric oxide is a marker of poor asthma control. J. Breath Res. 7, 026009.

    Not in our library10.1088/1752-7155/7/2/026009

  67. 67.

    Heinzmann A. Mao X. Q. Akaiwa M. Kreomer R. T. Gao P. S. Ohshima K. (2000 ). Genetic variants of IL-13 signalling and human asthma and atopy. Hum. Mol. Genet. 9, 549–559.

    Not in our library10.1093/hmg/9.4.549

  68. 68.

    Hershey G. K. Friedrich M. F. Esswein L. A. Thomas M. L. Chatila T. A. (1997 ). The association of atopy with a gain-of-function mutation in the alpha subunit of the interleukin-4 receptor. N. Engl. J. Med. 337, 1720–1725.

    Not in our library10.1056/nejm199712113372403

  69. 69.

    Hershey G. K. (2003 ). IL-13 receptors and signaling pathways: an evolving web. J. Allergy Clin. Immunol. 111, 677–690.

    Not in our library10.1067/mai.2003.1333

  70. 70.

    Hew M. Gillman A. Sutherland M. Wark P. Bowden J. Guo M. (2016 ). Real-life effectiveness of omalizumab in severe allergic asthma above the recommended dosing range criteria. Clin. Exp. Allergy 46, 1407–1415.

    Not in our library10.1111/cea.12774

  71. 71.
    Multidimensional endotyping in patients with severe asthma reveals inflammatory heterogeneity in matrix metalloproteinases and chitinase 3–like protein 1 · 2016
    No notice
  72. 72.

    Holgate S. T. Wenzel S. Postma D. S. Weiss S. T. Renz H. Sly P. D. (2015 ). Asthma. Nat. Rev. Dis. Primers. 1, 15025.

    Not in our library10.1038/nrdp.2015.25

  73. 73.

    Horie S. Okubo Y. Hossain M. Sato E. Nomura H. Koyama S. (1997 ). Interleukin-13 but not interleukin-4 prolongs eosinophil survival and induces eosinophil chemotaxis. Intern. Med. 36, 179–185.

    Not in our library10.2169/internalmedicine.36.179

  74. 74.

    Huang S. K. Xiao H. Q. Kleine-Tebbe J. Paciotti G. Marsh D. G. Lichtenstein L. M. (1995 ). IL-13 expression at the sites of allergen challenge in patients with asthma. J. Immunol. 155, 2688–2694.

    Not in our library

  75. 75.

    Ingram J. L. Kraft M. (2012 ). IL-13 in asthma and allergic disease: asthma phenotypes and targeted therapies. J. Allergy Clin. Immunol. 130, 829–842.

    Not in our library10.1016/j.jaci.2012.06.034

  76. 76.

    Jia Y. Fang X. Zhu X. Bai C. Zhu L. Jin M. (2016 ). IL-13(+) Type 2 innate lymphoid cells correlate with asthma control status and treatment response. Am. J. Respir. Cell Mol. Biol. 55, 675–683.

    Not in our library10.1165/rcmb.2016-0099oc

  77. 77.

    Kanoh S. Tanabe T. Rubin B. K. (2011 ). IL-13-induced MUC5AC production and goblet cell differentiation is steroid resistant in human airway cells. Clin. Exp. Allergy 41, 1747–1756.

    Not in our library10.1111/j.1365-2222.2011.03852.x

  78. 78.

    Kasaian M. T. Raible D. Marquette K. Cook T. A. Zhou S. Tan X. Y. (2011 ). IL-13 antibodies influence IL-13 clearance in humans by modulating scavenger activity of IL-13Ralpha2. J. Immunol. 187, 561–569.

    Not in our library10.4049/jimmunol.1100467

  79. 79.

    Kaur R. Chupp G. (2019 ). Phenotypes and endotypes of adult asthma: Moving toward precision medicine. J. Allergy Clin. Immunol. 144, 1–12.

    Not in our library10.1016/j.jaci.2019.05.031

  80. 80.

    Kaur D. Hollins F. Woodman L. Yang W. Monk P. May R. (2006 ). Mast cells express IL-13R alpha 1: IL-13 promotes human lung mast cell proliferation and Fc epsilon RI expression. Allergy 61, 1047–1053.

    Not in our library10.1111/j.1398-9995.2006.01139.x

  81. 81.

    Kawakami K. Taguchi J. Murata T. Puri R. K. (2001 ). The interleukin-13 receptor alpha2 chain: an essential component for binding and internalization but not for interleukin-13-induced signal transduction through the STAT6 pathway. Blood 97, 2673–2679.

    Not in our library10.1182/blood.v97.9.2673

  82. 82.

    Kerkhof M. Tran T. N. Soriano J. B. Golam S. Gibson D. Hillyer E. V. (2018 ). Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population. Thorax 73, 116–124.

    Not in our library10.1136/thoraxjnl-2017-210531

  83. 83.

    Khatri S. Moore W. Gibson P. G. Leigh R. Bourdin A. Maspero J. (2019 ). Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J. Allergy Clin. Immunol. 143, 1742–1751 e1747.

    Not in our library10.1016/j.jaci.2018.09.033

  84. 84.

    Kirstein F. Nieuwenhuizen N. E. Jayakumar J. Horsnell W. G. C. Brombacher F. (2016 ). Role of IL-4 receptor alpha-positive CD4(+) T cells in chronic airway hyperresponsiveness. J. Allergy Clin. Immunol. 137, 1852–1862 e1859.

    Not in our library10.1016/j.jaci.2015.10.036

  85. 85.

    Komai M. Tanaka H. Masuda T. Nagao K. Ishizaki M. Sawada M. (2003 ). Role of Th2 responses in the development of allergen-induced airway remodelling in a murine model of allergic asthma. Br. J. Pharmacol. 138, 912–920.

    Not in our library10.1038/sj.bjp.0705105

  86. 86.

    Kondo M. Tamaoki J. Takeyama K. Isono K. Kawatani K. Izumo T. (2006 ). Elimination of IL-13 reverses established goblet cell metaplasia into ciliated epithelia in airway epithelial cell culture. Allergol. Int. 55, 329–336.

    Not in our library10.2332/allergolint.55.329

  87. 87.

    Kroegel C. Julius P. Matthys H. Virchow J. C. Jr. Luttmann W. (1996 ). Endobronchial secretion of interleukin-13 following local allergen challenge in atopic asthma: relationship to interleukin-4 and eosinophil counts. Eur. Respir. J. 9, 899–904.

    Not in our library10.1183/09031936.96.09050899

  88. 88.

    Kruse S. Japha T. Tedner M. Sparholt S. H. Forster J. Kuehr J. (1999 ). The polymorphisms S503P and Q576R in the interleukin-4 receptor alpha gene are associated with atopy and influence the signal transduction. Immunology 96, 365–371.

    Not in our library10.1046/j.1365-2567.1999.00705.x

  89. 89.

    Kumar R. K. Herbert C. Webb D. C. Li L. Foster P. S. (2004 ). Effects of anticytokine therapy in a mouse model of chronic asthma. Am. J. Respir. Crit. Care Med. 170, 1043–1048.

    Not in our library10.1164/rccm.200405-681oc

  90. 90.

    Kuperman D. A. Huang X. Koth L. L. Chang G. H. Dolganov G. M. Zhu Z. (2002 ). Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. Nat. Med. 8, 885–889.

    Not in our library10.1038/nm734

  91. 91.

    Lang D. M. Polansky M. (1994 ). Patterns of asthma mortality in Philadelphia from 1969 to 1991. N. Engl. J. Med. 331, 1542–1546.

    Not in our library10.1056/nejm199412083312302

  92. 92.

    Lange P. Ulrik C. S. Vestbo J. (1996 ). Mortality in adults with self-reported asthma. Copenhagen City Heart Study Group. Lancet 347, 1285–1289.

    Not in our library10.1016/s0140-6736(96)90937-x

  93. 93.

    Laporte J. C. Moore P. E. Baraldo S. Jouvin M. H. Church T. L. Schwartzman I. N. (2001 ). Direct effects of interleukin-13 on signaling pathways for physiological responses in cultured human airway smooth muscle cells. Am. J. Respir. Crit. Care Med. 164, 141–148.

    Not in our library10.1164/ajrccm.164.1.2008060

  94. 94.

    LaPorte S. L. Juo Z. S. Vaclavikova J. Colf L. A. Qi X. Heller N. M. (2008 ). Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system. Cell 132, 259–272.

    Not in our library10.1016/j.cell.2007.12.030

  95. 95.

    Leigh R. Ellis R. Wattie J. Donaldson D. D. Inman M. D. (2004 ). Is interleukin-13 critical in maintaining airway hyperresponsiveness in allergen-challenged mice? Am. J. Respir. Crit. Care Med. 170, 851–856.

    Not in our library10.1164/rccm.200311-1488oc

  96. 96.

    Li L. Xia Y. Nguyen A. Lai Y. H. Feng L. Mosmann T. R. (1999 ). Effects of Th2 cytokines on chemokine expression in the lung: IL-13 potently induces eotaxin expression by airway epithelial cells. J. Immunol. 162, 2477–2487.

    Not in our library

  97. 97.

    Lightwood D. Tservistas M. Zehentleitner M. Sarkar K. Turner A. Bracher M. (2018 ). Efficacy of an inhaled IL-13 antibody fragment in a model of chronic asthma. Am. J. Respir. Crit. Care Med. 198, 610–619.

    Not in our library10.1164/rccm.201712-2382oc

  98. 98.

    Lin D. C. (2011 ). Association between severity of asthma and degree of chronic rhinosinusitis. Am. J. Rhinol. Allergy 205–208.

    Not in our library10.2500/ajra.2011.25.3613

  99. 99.

    Liu Z. Li P. Wang J. Fan Q. Yan P. Zhang X. (2014 ). A meta-nalysis of IL-13 polymorphisms and pediatric asthma risk. Med. Sci. Monit. 20, 2617–2623.

    Not in our library10.12659/msm.891017

  100. 100.

    Liu J. Li Y. Y. Andiappan A. K. Yan Y. Tan K. S. Ong H. H. (2018 ). Role of IL-13Ralpha2 in modulating IL-13-induced MUC5AC and ciliary changes in healthy and CRSwNP mucosa. Allergy 73, 1673–1685.

    Not in our library10.1111/all.13424

  101. 101.

    Lozano R. Naghavi M. Foreman K. Lim S. Shibuya K. Aboyans V. (2012 ). Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2095–2128.

    Not in our library10.1016/s0140-6736(12)61728-0

  102. 102.

    Lupardus P. J. Birnbaum M. E. Garcia K. C. (2010 ). Molecular basis for hared cytokine recognition revealed in the structure of an unusually high ffinity complex between IL-13 and IL-13Ralpha2. Structure 18, 332–342.

    Not in our library10.1016/j.str.2010.01.003

  103. 103.

    Luttmann W. Knoechel B. Foerster M. Matthys H. Virchow J. C. Jr. Kroegel C. (1996 ). Activation of human eosinophils by IL-13. Induction of CD69 urface antigen, its relationship to messenger RNA expression, and promotion of ellular viability. J. Immunol. 157, 1678–1683.

    Not in our library

  104. 104.

    Ma Y. HayGlass K. T. Becker A. B. Fan Y. Yang X. Basu S. (2007 ). Novel recombinant interleukin-13 peptide-based vaccine reduces airway llergic inflammatory responses in mice. Am. J. Respir. Crit. Care Med. 176, 439–445.

    Not in our library10.1164/rccm.200610-1405oc

  105. 105.

    Ma Y. Halayko A. J. Basu S. Guan Q. Weiss C. R. Ma A. G. (2013 ). Sustained suppression of IL-13 by a vaccine attenuates airway inflammation and remodeling in mice. Am. J. Respir. Cell Mol. Biol. 48, 540–549.

    Not in our library10.1165/rcmb.2012-0060oc

  106. 106.

    Macchia D. Melioli G. Pravettoni V. Nucera E. Piantanida M. Aminati M. (2015 ). Guidelines for the use and interpretation of diagnostic ethods in adult food allergy. Clin. Mol. Allergy 13, 27.

    Not in our library10.1186/s12948-15-0033-9

  107. 107.

    Marone G. Triggiani M. de Paulis A. (2005 ). Mast cells and basophils: friends as well as foes in bronchial asthma? Trends Immunol. 26, 25–31.

    Not in our library10.1016/j.it.2004.10.010

  108. 108.

    Marone G. Galdiero M. R. Pecoraro A. Pucino V. Criscuolo G. Triassi M. (2019 ). Prostaglandin D2 receptor antagonists in allergic disorders: safety, efficacy, and future perspectives. Expert Opin. Invest. Drugs 28, 73–84.

    Not in our library10.1080/13543784.2019.1555237

  109. 109.

    Martinez F. D. (2002 ). What have we learned from the Tucson Children's espiratory Study? Paediatr. Respir. Rev. 3, 193–197.

    Not in our library10.1016/s1526-542(02)00188-4

  110. 110.

    Martinez-Nunez R. T. Louafi F. Sanchez-Elsner T. (2011 ). The nterleukin 13 (IL-13) pathway in human macrophages is modulated by icroRNA-155 via direct targeting of interleukin 13 receptor alpha1 IL13Ralpha1). J. Biol. Chem. 286, 1786–1794.

    Not in our library10.1074/jbc.m110.169367

  111. 111.

    McCormick S. M. Heller N. M. (2015 ). Commentary: IL-4 and IL-13 receptors and signaling. Cytokine 75, 38–50.

    Not in our library10.1016/j.cyto.2015.05.023

  112. 112.

    McKenzie G. J. Fallon P. G. Emson C. L. Grencis R. K. cKenzie A. N. (1999 ). Simultaneous disruption of interleukin (IL)-4 and IL-13 efines individual roles in T helper cell type 2-mediated responses. J. Exp. Med. 89, 1565–1572.

    Not in our library10.1084/jem.189.10.1565

  113. 113.

    Mei Q. Qu J. (2017 ). Interleukin-13 +2044 G/A and +1923C/T olymorphisms are associated with asthma susceptibility in Asians: a meta-nalysis. Med. (Baltimore) 96, e9203.

    Not in our library10.1097/md.0000000000009203

  114. 114.

    Metha A. K. (2016 ). Rhinovirus infection interferes with induction of tolerance to aeroantigens through OX40 ligand, thymic stromal lymphopoietin, and IL-33. J. Allergy Clin. Immunol. 137, 278–288.

    Not in our library10.1016/j.jaci.2015.05.007

  115. 115.

    Minty A. Chalon P. Derocq J. M. Dumont X. Guillemot J. C. Kaghad M. (1993 ). Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature 362, 248–250.

    Not in our library10.1038/362248a0

  116. 116.

    Munitz A. Brandt E. B. Mingler M. Finkelman F. D. Rothenberg M. E. (2008 ). Distinct roles for IL-13 and IL-4 via IL-13 receptor alpha1 and the type II L-4 receptor in asthma pathogenesis. Proc. Natl. Acad. Sci. U. S. A. 105, 7240–7245.

    Not in our library10.1073/pnas.0802465105

  117. 117.

    Naseer T. Minshall E. M. Leung D. Y. Laberge S. Ernst P. Martin R. J. (1997 ). Expression of IL-12 and IL-13 mRNA in asthma and their modulation in esponse to steroid therapy. Am. J. Respir. Crit. Care Med. 155, 845–851.

    Not in our library10.1164/ajrccm.155.3.9117015

  118. 118.

    Nilsson G. Nilsson K. (1995 ). Effects of interleukin (IL)-13 on immediate-early response gene expression, phenotype and differentiation of human mast ells. Comparison with IL-4. Eur. J. Immunol. 25, 870–873.

    Not in our library10.1002/eji.1830250337

  119. 119.

    Ober C. Leavitt S. A. Tsalenko A. Howard T. D. Hoki D. M. Daniel R. (2000 ). Variation in the interleukin 4-receptor alpha gene confers susceptibility to asthma and atopy in ethnically diverse populations. Am. J. Hum. Genet. 66, 517–526.

    Not in our library10.1086/302781

  120. 120.

    Ochensberger B. Daepp G. C. Rihs S. Dahinden C. A. (1996 ). Human lood basophils produce interleukin-13 in response to IgE-receptor-dependent and independent activation. Blood 88, 3028–3037.

    Not in our library10.1182/blood.v88.8.3028.bloodjournal8883028

  121. 121.

    Oetjen L. K. Mack M. R. Feng J. Whelan T. M. Niu H. Guo C. J. (2017 ). Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell 171, 217–228 e213.

    Not in our library10.1016/j.cell.2017.08.006

  122. 122.

    Oettgen H. C. Geha R. S. (2001 ). IgE regulation and roles in asthma pathogenesis. J. Allergy Clin. Immunol. 107, 429–440.

    Not in our library10.1067/mai.2001.113759

  123. 123.

    Ortega H. G. Liu M. C. Pavord I. D. Brusselle G. G. FitzGerald J. M. Chetta A. (2014 ). Mepolizumab treatment in patients with severe eosinophilic asthma. N. Engl. J. Med. 371, 1198–1207.

    Not in our library10.1056/nejmoa1403290

  124. 124.

    Panettieri R. A. Sjobring U. Peterffy A. Wessman P. Bowen K. Piper E. (2018 ). Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials. Lancet Respir. Med. 6, 511–525.

    Not in our library10.1016/s2213-2600(18)30184-x

  125. 125.

    Patella V. Florio G. Petraroli A. Marone G. (2000 ). HIV-1 gp120 induces L-4 and IL-13 release from human Fc epsilon RI+ cells through interaction with he VH3 region of IgE. J. Immunol. 164, 589–595.

    Not in our library10.4049/jimmunol.164.2.589

  126. 126.

    Pearlman A. N. Chandra R. K. Chang D. Conley D. B. Tripathi-Peters A. Grammer L. (2009 ). Relationships between severity of chronic hinosinusitis and nasal polyposis, asthma, and atopy. Am. J. Rhinol. Allergy 23, 45–148.

    Not in our library10.2500/ajra.2009.23.3284

  127. 127.

    Pepper A. N. Renz H. Casale T. B. Garn H. (2017 ). Biologic Therapy and ovel Molecular Targets of Severe Asthma. J. Allergy Clin. Immunol. Pract. 5, 909–916.

    Not in our library10.1016/j.jaip.2017.04.038

  128. 128.

    Pham T. H. Bak Y. Oh J. W. Hong J. Lee S. Hong J. T. (2019 ). Inhibition of IL-13 and IL-13Ralpha2 Expression by IL-32theta in Human Monocytic Cells Requires PKCdelta and STAT3 Association. Int. J. Mol. Sci. 20, E1949.

    Not in our library10.3390/ijms20081949

  129. 129.

    Piper E. Brightling C. Niven R. Oh C. Faggioni R. Poon K. (2013 ). A hase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Respir. J. 41, 330–338.

    Not in our library10.1183/09031936.00223411

  130. 130.

    Pope S. M. Brandt E. B. Mishra A. Hogan S. P. Zimmermann N. Matthaei K. I. (2001 ). IL-13 induces eosinophil recruitment into the lung by an L-5- and eotaxin-dependent mechanism. J. Allergy Clin. Immunol. 108, 594–601.

    Not in our library10.1067/mai.2001.118600

  131. 131.

    Poposki J. A. Klingler A. I. Tan B. K. Soroosh P. Banie H. Lewis G. (2017 ). Group 2 innate lymphoid cells are elevated and activated in chronic rhinosinusitis with nasal polyps. Immun. Inflammation Dis. 5, 233–243.

    Not in our library10.1002/iid3.161

  132. 132.

    Prieto J. Lensmar C. Roquet A. van der Ploeg I. Gigliotti D. Eklund A. (2000 ). Increased interleukin-13 mRNA expression in bronchoalveolar lavage ells of atopic patients with mild asthma after repeated low-dose allergen rovocations. Respir. Med. 94, 806–814.

    Not in our library10.1053/rmed.2000.0826

  133. 133.

    Punnonen J. Aversa G. Cocks B. G. McKenzie A. N. Menon S. Zurawski G. (1993 ). Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells. Proc. Natl. Acad. Sci. U. S. A. 90, 730–3734.

    Not in our library10.1073/pnas.90.8.3730

  134. 134.

    Rabe K. F. Nair P. Brusselle G. Maspero J. F. Castro M. Sher L. (2018 ). Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N. Engl. J. Med. 378, 2475–2485.

    Not in our library10.1056/nejmoa1804093

  135. 135.

    Ragab A. Clement P. Vincken W. (2004 ). Objective assessment of lower airway involvement in chronic rhinosinusitis. Am. J. Rhinol. 18, 15–21.

    Not in our library10.1177/194589240401800105

  136. 136.

    Ramirez-Carrozzi V. Sambandam A. Zhou M. Yan D. Kang J. Wu X. (2017 ). Combined blockade of the IL-13 and IL-33 pathways leads to a greater inhibition of type 2 inflammation over inhibition of either pathway alone. J. Allergy Clin. Immunol. 139, 705–708 e706.

    Not in our library10.1016/j.jaci.2016.08.026

  137. 137.

    Redrup A. C. Howard B. P. MacGlashan D. W. Kagey-Sobotka A. Lichtenstein L. M. Schroeder J. T. (1998 ). Differential regulation of IL-4 and IL-13 ecretion by human basophils: their relationship to histamine release in mixed eukocyte cultures. J. Immunol. 160, 1957–1964.

    Not in our library

  138. 138.

    Ricciardolo F. L. M. Sorbello V. Folino A. Gallo F. Massaglia G. M. avata G. (2017 ). Identification of IL-17F/frequent exacerbator endotype in sthma. J. Allergy Clin. Immunol. 140, 395–406.

    Not in our library10.1016/j.jaci.2016.10.034

  139. 139.

    Robinson D. Humbert M. Buhl R. Cruz A. A. Inoue H. Korom S. (2017 ). Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clin. Exp. Allergy 47, 161–175.

    Not in our library10.1111/cea.12880

  140. 140.

    Rosenberg H. F. Phipps S. Foster P. S. (2007 ). Eosinophil trafficking in allergy and asthma. J. Allergy Clin. Immunol. 119, 1303–1310.

    Not in our library10.1016/j.jaci.2007.03.048

  141. 141.

    Russell R. J. Chachi L. FitzGerald J. M. Backer V. Olivenstein R. itlestad I. L. (2018 ). Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial. Lancet Respir. Med. 6, 499–510.

    Not in our library10.1016/s2213-2600(18)30201-7

  142. 142.

    Saha S. K. Berry M. A. Parker D. Siddiqui S. Morgan A. May R. (2008 ). Increased sputum and bronchial biopsy IL-13 expression in severe asthma. Allergy Clin. Immunol. 121, 685–691.

    Not in our library10.1016/j.jaci.2008.01.005

  143. 143.

    Samitas K. Delimpoura V. Zervas E. Gaga M. (2015 ). Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current nowledge and future perspectives. Eur. Respir. Rev. 24, 594–601.

    Not in our library10.1183/16000617.00001715

  144. 144.

    Samitas K. Zervas E. Gaga M. (2017 ). T2-low asthma: current approach to diagnosis and therapy. Curr. Opin. Pulm. Med. 23, 48–55.

    Not in our library10.1097/mcp.0000000000000342

  145. 145.

    Schmid-Grendelmeier P. Altznauer F. Fischer B. Bizer C. Straumann A. Menz G. (2002 ). Eosinophils express functional IL-13 in eosinophilic nflammatory diseases. J. Immunol. 169, 1021–1027.

    Not in our library10.4049/jimmunol.169.2.1021

  146. 146.

    Sekiya K. Nakatani E. Fukutomi Y. Kaneda H. Iikura M. Yoshida M. (2016 ). Severe or life-threatening asthma exacerbation: patient heterogeneity dentified by cluster analysis. Clin. Exp. Allergy 46, 1043–1055.

    Not in our library10.1111/cea.12738

  147. 147.

    Settipane G. A. Chafee F. H. (1977 ). Nasal polyps in asthma and rhinitis. A eview of 6,037 patients. J. Allergy Clin. Immunol. 59, 17–21.

    Not in our library10.1016/0091-749(77)90171-3

  148. 148.

    Shimokawa C. Kanaya T. Hachisuka M. Ishiwata K. Hisaeda H. Kurashima Y. (2017 ). Mast cells are crucial for induction of group 2 innate ymphoid cells and clearance of helminth infections. Immunity 46, 863–874 864.

    Not in our library10.1016/j.immuni.2017.04.017

  149. 149.

    Singh D. Kane B. Molfino N. A. Faggioni R. Roskos L. Woodcock A. (2010 ). A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma. MC Pulm. Med. 10, 3.

    Not in our library10.1186/1471-2466-10-3

  150. 150.

    Steinke J. W. (2004 ). Anti-interleukin-4 therapy. Immunol. Allergy Clin. North Am. 24, 599–614.

    Not in our library10.1016/j.iac.2004.06.008

  151. 151.

    Terl M. Sedlak V. Cap P. Dvorakova R. Kasak V. Koci T. (2017 ). Asthma management: a new phenotype-based approach using presence of osinophilia and allergy. Allergy 72, 1279–1287.

    Not in our library10.1111/all.13165

  152. 152.

    Truyen E. Coteur L. Dilissen E. Overbergh L. Dupont L. J. Ceuppens J. L. (2006 ). Evaluation of airway inflammation by quantitative Th1/Th2 cytokine mRNA measurement in sputum of asthma patients. Thorax 61, 202–208.

    Not in our library10.1136/thx.2005.052399

  153. 153.

    Varricchi G. Senna G. Loffredo S. Bagnasco D. Ferrando M. Anonica G. W. (2017 ). Reslizumab and Eosinophilic Asthma: One Step Closer to recision Medicine? Front. Immunol. 8, 242.

    Not in our library10.3389/fimmu.2017.00242

  154. 154.

    Varricchi G. Galdiero M. R. Loffredo S. Lucarini V. Marone G. Mattei F. (2018 a). Eosinophils: the unsung heroes in cancer? Oncoimmunology 7, 1393134.

    Not in our library10.1080/2162402x.2017.1393134

  155. 155.

    Varricchi G. Loffredo S. Galdiero M. R. Marone G. Cristinziano L. Granata F. (2018 b). Innate effector cells in angiogenesis and lymphangiogenesis. Curr. Opin. Immunol. 53, 152–160.

    Not in our library10.1016/j.coi.2018.05.002

  156. 156.
    Thymic Stromal Lymphopoietin Isoforms, Inflammatory Disorders, and Cancer · 2018
    No notice
  157. 157.

    Varricchi G. Raap U. Rivellese F. Marone G. Gibbs B. F. (2018 d). Human mast cells and basophils-How are they similar how are they different? Immunol. Rev. 282, 8–34.

    Not in our library10.1111/imr.12627

  158. 158.

    Varricchi G. Rossi F. W. Galdiero M. R. Granata F. Criscuolo G. Spadaro G. (2019 ). Physiological roles of mast cells: collegium internationale allergologicum update 2019. Int. Arch. Allergy Immunol. 179, 247–261.

    Not in our library10.1159/000500088

  159. 159.

    Venkataramani S. Low S. Weigle B. Dutcher D. Jerath K. Menzenski M. (2018 ). Design and characterization of Zweimab and Doppelmab, high ffinity dual antagonistic anti-TSLP/IL13 bispecific antibodies. Biochem. Biophys. Res. Commun. 504, 19–24.

    Not in our library10.1016/j.bbrc.2018.08.064

  160. 160.

    Verma M. Liu S. Michalec L. Sripada A. Gorska M. M. Alam R. (2018 ). Experimental asthma persists in IL-33 receptor knockout mice because of the emergence of thymic stromal lymphopoietin-driven IL-9(+) and IL-13(+) type 2 innate lymphoid cell subpopulations. J. Allergy Clin. Immunol. 142, 793–803 e798.

    Not in our library10.1016/j.jaci.2017.10.020

  161. 161.

    Wallrapp A. Riesenfeld S. J. Burkett P. R. Kuchroo V. K. (2018 ). Type 2 innate lymphoid cells in the induction and resolution of tissue inflammation. Immunol. Rev. 286, 53–73.

    Not in our library10.1111/imr.12702

  162. 162.

    Walter D. M. McIntire J. J. Berry G. McKenzie A. N. Donaldson D. D. DeKruyff R. H. (2001 ). Critical role for IL-13 in the development of allergen-induced airway hyperreactivity. J. Immunol. 167, 4668–4675.

    Not in our library10.4049/jimmunol.167.8.4668

  163. 163.

    Wang I. M. Lin H. Goldman S. J. Kobayashi M. (2004 ). STAT-1 is activated by IL-4 and IL-13 in multiple cell types. Mol. Immunol. 41, 873–884.

    Not in our library10.1016/j.molimm.2004.04.027

  164. 164.

    Webb D. C. McKenzie A. N. Koskinen A. M. Yang M. Mattes J. Foster P. S. (2000 ). Integrated signals between IL-13, IL-4, and IL-5 regulate airways hyperreactivity. J. Immunol. 165, 108–113.

    Not in our library10.4049/jimmunol.165.1.108

  165. 165.

    Wenzel S. Wilbraham D. Fuller R. Getz E. B. Longphre M. (2007 ). Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 370, 1422–1431.

    Not in our library10.1016/s0140-6736(07)61600-6

  166. 166.

    Wenzel S. E. (2012 ). Asthma phenotypes: the evolution from clinical to molecular approaches. Nat. Med. 18, 716–725.

    Not in our library10.1038/nm.2678

  167. 167.

    Wills-Karp M. Luyimbazi J. Xu X. Schofield B. Neben T. Y. Karp C. L. (1998 ). Interleukin-13: central mediator of allergic asthma. Science 282, 2258–2261.

    Not in our library10.1126/science.282.5397.2258

  168. 168.

    Wills-Karp M. (2001 ). IL-12/IL-13 axis in allergic asthma. J. Allergy Clin. Immunol. 107, 9–18.

    Not in our library10.1067/mai.2001.112265

  169. 169.

    Wood N. Whitters M. J. Jacobson B. A. Witek J. Sypek J. P. Kasaian M. (2003 ). Enhanced interleukin (IL)-13 responses in mice lacking IL-13 receptor alpha 2. J. Exp. Med. 197, 703–709.

    Not in our library10.1084/jem.20020906

  170. 170.

    Wynn T. A. (2015 ). Type 2 cytokines: mechanisms and therapeutic strategies. Nat. Rev. Immunol. 15, 271–282.

    Not in our library10.1038/nri3831

  171. 171.

    Xu Y. Li J. Ding Z. Li B. Yu Z. Tan W. (2017 ). Association between IL-13 +1923C/T polymorphism and asthma risk: a meta-analysis based on 26 case-control studies. Biosci. Rep. 37, BSR20160505.

    Not in our library10.1042/bsr20160505

  172. 172.

    Zhang F. Q. Han X. P. Zhang F. Ma X. Xiang D. Yang X. M. (2017 ). Therapeutic efficacy of a co-blockade of IL-13 and IL-25 on airway inflammation and remodeling in a mouse model of asthma. Int. Immunopharmacol. 46, 133–140.

    Not in our library10.1016/j.intimp.2017.03.005

  173. 173.

    Zhang Y. Cheng J. Li Y. He R. Pan P. Su X. (2019 ). The safety and efficacy of anti-IL-13 treatment with Tralokinumab (CAT-354) in moderate to severe asthma: a systematic review and meta-analysis. J. Allergy Clin. Immunol. Pract. 2661–2671.

    Not in our library10.1016/j.jaip.2019.05.030

  174. 174.

    Zhu Z. Homer R. J. Wang Z. Chen Q. Geba G. P. Wang J. (1999 ). Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J. Clin. Invest. 103, 779–788.

    Not in our library10.1172/jci5909

Cited by papers we hold 2

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.